Zhang Xiaoping, Zhang Liang, Yang Hongmei, Huang Xu, Otu Hasan, Libermann Towia A, DeWolf William C, Khosravi-Far Roya, Olumi Aria F
Department of Urology, Massachusetts General Hospital, Boston, MA 02114, USA.
Cancer Res. 2007 Oct 1;67(19):9425-34. doi: 10.1158/0008-5472.CAN-07-1310.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L promotes apoptosis in cancer cells while sparing normal cells. Although many cancers are sensitive to TRAIL-induced apoptosis, some evade the proapoptotic effects of TRAIL. Therefore, differentiating molecular mechanisms that distinguish between TRAIL-sensitive and TRAIL-resistant tumors are essential for effective cancer therapies. Here, we show that c-Fos functions as a proapoptotic agent by repressing the antiapoptotic molecule c-FLIP(L). c-Fos binds the c-FLIP(L) promoter, represses its transcriptional activity, and reduces c-FLIP(L) mRNA and protein levels. Therefore, c-Fos is a key regulator of c-FLIP(L), and activation of c-Fos determines whether a cancer cell will undergo cell death after TRAIL treatment. Strategies to activate c-Fos or inhibit c-FLIP(L) may potentiate TRAIL-based proapoptotic therapies.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)/Apo-2L可促进癌细胞凋亡,同时对正常细胞无影响。尽管许多癌症对TRAIL诱导的凋亡敏感,但有些癌症可逃避TRAIL的促凋亡作用。因此,区分TRAIL敏感和TRAIL耐药肿瘤的分子机制对于有效的癌症治疗至关重要。在此,我们表明c-Fos通过抑制抗凋亡分子c-FLIP(L)发挥促凋亡作用。c-Fos结合c-FLIP(L)启动子,抑制其转录活性,并降低c-FLIP(L)的mRNA和蛋白水平。因此,c-Fos是c-FLIP(L)的关键调节因子,c-Fos的激活决定了癌细胞在TRAIL治疗后是否会发生细胞死亡。激活c-Fos或抑制c-FLIP(L)的策略可能会增强基于TRAIL的促凋亡疗法。